ICU Medical Technologies’ Post

Anteris Technologies has achieved a significant breakthrough in heart valve treatment with the completion of three complex valve-in-valve (ViV) procedures using its innovative DurAVR™ transcatheter #heart valve. These procedures were under Health Canada’s special access program (SAP) which allows healthcare professionals to access unlicensed #medical devices, such as DurAVR, for emergency use when conventional therapies have failed, are unavailable or are unsuitable to treat a patient. The transcatheter ViV replacement is performed by implanting a #transcatheter heart valve within a failing bioprosthetic aortic valve, a less invasive procedure compared with reoperative surgical aortic valve replacement. More at http://ow.ly/QEII105ahFN #ASX #OTC #AVR #AMEUF #Proactive #ProactiveInvestors

* CTO PCI, Well planning, Nice results * 54y old gentleman with history of Diabetes & Angina pectoris for 3 months presented with ACS LVEF: 30% Radial SCA revealed 2VD (LAD&RCA-CTO) Low syntax score whats the best revascularization strategy ? after shared-decision making Successful PCI on LAD was done and thereafter patient undergone medical therapy after 1 month of GDMT patient remained symptomatic Planned for elective RCA-CTO pci using dual-access (J-CTO score: 1) Access: dual-access (Right TRA & TFA) Initial strategy: Antegrade approach Microcatheter: Corsair-proXS GW: Started with Fielder XT, couldnt penetrate proximal cap, switched to Gaia-Next 1 which was entered subintimal at first easaily reentered the true lumen Corsair MC coundnt pass the tight lesion Even 1.0 SapphirePro balloon cound not pass the CTO lesion But BLIMP solved the problem ! (although using side-branch anchoring balloon might be helpful) Predilation was done using 1.25 & long 2.0 NC balloon 2 Overlapping DESs (Xience 2.5 x 48 & Ultimaster 3.5 x 38) were deployed Aggresive postdilation 3.0 for distal portion and 3.5 for proximal segment was carried out Good TIMI flow & result (unfortunately IVUS catheter was not available for procedural assessment) Patient follow-up: Symptomatic free 2 days after the CTO-PCI #interventionalcardiology #angioplasty #cto #asahi #imds

From MassDevice: Johnson & Johnson acquisition of Shockwave Medical for approximately $13.1 billion marks a significant shift in the landscape of #surgicalrobotics and medical technology. By integrating Shockwave's intravascular lithotripsy (IVL) technology, known for its innovative approach to treating calcified arterial plaque, Johnson & Johnson significantly bolsters its #MedTech portfolio, particularly in #cardiovascular intervention. This move not only highlights the growing importance of advanced catheter-based treatments in managing coronary and #peripheralarterydisease but also underscores the industry's trend towards consolidating high-growth market segments in cardiovascular care. #MedicalDevices #RoboticSurgery #SurgicalRobot #HealthTechInnovation #Aquisition

Evasc Neurovascular Expands European Presence: Milestone Achievement with Eclips Device and Launch of German Subsidiary Evasc Neurovascular, a leading medical technology company specializing in endovascular repair solutions for cerebral aneurysms, proudly announces its strategic growth initiatives. The company has achieved a milestone of 120 successful cases with its innovative Eclips device and is expanding its European operations with the establishment of a new subsidiary, Evasc Neurovascular GmbH, headquartered in Germany. This expansion signifies a significant leap forward in Evasc's commitment to providing enhanced neurovascular care solutions in Europe. By establishing a direct presence in Germany, Evasc aims to facilitate more efficient services and direct sales, solidifying its position as a key player in the European market. In parallel with this expansion, Evasc reports noteworthy progress in the France EESIS trial, a crucial component of the company's ongoing efforts to validate the efficacy and safety of its groundbreaking neurovascular treatments. The strategic move into Germany positions Evasc to contribute even more significantly to the advancement of neurovascular care throughout Europe. Evasc's success extends beyond geographical boundaries, with increasing recognition and adoption within the NeuroInterventional Radiology (NIR) community. Its cutting-edge solutions have demonstrated remarkable promise, particularly in the treatment of wide neck bifurcation aneurysms—an area that has historically presented challenges within neurovascular care. In the current year alone, Evasc has successfully treated 80 patients, achieving a commendable milestone in the company's history. This accomplishment underscores Evasc's unwavering dedication to improving patient outcomes and advancing neurovascular care. As part of Evasc Neurovascular's commitment to advancing patient care, the establishment of Evasc Neurovascular GmbH in Germany underscores the company's dedication to localizing support and resources for its European clientele. The move aims to foster stronger relationships with healthcare professionals and institutions, ensuring timely access to Evasc's innovative neurovascular solutions. This strategic expansion aligns with the company's vision of making a meaningful impact on the global landscape of cerebral aneurysm treatment, reinforcing Evasc Neurovascular's position as a trusted partner in the pursuit of better care and improved outcomes. "Our expansion into Germany and our ongoing success in clinical trials and patient treatments are demonstrations of the Evasc dedication to excellence and paving new ground in the world of neurovascular health,” commented a spokesperson from Evasc Neurovascular. “This positive momentum will only continue. We are confident our company will continue to be instrumental in shaping the landscape of neurovascular care worldwide."

Boston Scientific received CE Mark for its Acurate Prime Aortic Valve System. The TAVR System is set to enhance precision and efficiency in transcatheter aortic valve replacement (TAVR) procedures. This holds notable implications for healthcare: 1. 𝐄𝐱𝐩𝐚𝐧𝐝𝐞𝐝 𝐀𝐜𝐜𝐞𝐬𝐬: This system could make advanced cardiovascular care more accessible to patients across Europe, particularly those who might not have previously qualified for traditional surgical interventions. 2. 𝐈𝐦𝐩𝐫𝐨𝐯𝐞𝐝 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐎𝐮𝐭𝐜𝐨𝐦𝐞𝐬: With better precision in valve placement, patients may experience fewer complications and faster recoveries. 3. 𝐐𝐮𝐢𝐜𝐤𝐞𝐫, 𝐂𝐨𝐧𝐭𝐫𝐨𝐥𝐥𝐞𝐝 𝐃𝐞𝐩𝐥𝐨𝐲𝐦𝐞𝐧𝐭: Streamlined device preparation and advanced technology enable faster, more precise valve deployment, potentially reducing procedure time and improving efficiency. 4. 𝐌𝐢𝐧𝐢𝐦𝐚𝐥𝐥𝐲 𝐈𝐧𝐯𝐚𝐬𝐢𝐯𝐞 𝐂𝐚𝐫𝐞: This system's availability could support the increasing demand for minimally invasive heart valve treatments, and alleviate pressure on traditional surgical resources. #BostonScientific #TAVR #Cardiovascular #Healthcareinnovation #Medicaldevices #Cardiovascularcare #Healthcareaccess

Did you know? Back in 2004, the SynCardia 70cc Total Artificial Heart received FDA approval. This groundbreaking milestone paved the way for countless lives to be saved and transformed by this revolutionary technology. Since then, the SynCardia Total Artificial Heart has continued to make a profound impact, providing hope and a new lease on life for patients facing end-stage heart failure. As we reflect on this significant achievement, we're reminded of the power of innovation and the importance of advancing medical technology to improve patient outcomes. Here's to many more years of innovation, progress, and lifesaving moments with the SynCardia Total Artificial Heart! #SynCardia #cardiacsurgery #Innovation #heartfailure #cardiology #cardiovascular #cardiovasculardisease #cardiacsurgery #CVD #RVAD #LVAD #BiVAS #LVAS #FILVAS #TAH #ECMO #impella #MCS #artificialheart #hearttransplant #medtech #medicaldevices #meddevice #givingthegiftoftime #PicardMedical #BiVACOR #Carmat #Aeson #Scandinavianrealheart #realheart

Companies continue to develop next-generation transcatheter valves with features like longer durability, better hemodynamic performance, and improved positioning during implantation. We assess the clinical data behind these improvements to predict future adoption. Another focus is the durability of TAVR valves, which could expand usage in younger patients if long-term results prove favorable. Additionally, valve-in-valve procedures, where a new valve is implanted within a failing TAVR or SAVR valve, are becoming increasingly relevant. Tracking advancements that lower complication rates (e.g., lower pacemaker implantation rates, paravalvular leak prevention) can also give companies a competitive edge. Better clinical outcomes lead to higher adoption by physicians and hospitals. #cardiac #implant #healthcare #medtronic #technology

💙 Boston Scientific's ground-breaking modular, leadless cardiac rhythm management system has shown promising early results as demonstrated at #ESCCOngress2024! This innovative system combines Boston Scientific's new Empower Leadless Pacemaker and their Emblem Subcutaneous Implantable Defibrillator (S-ICD) 📊 Key findings from the MODULAR ATP study on Boston Scientific's system: ✅ High successful implantation rate ✅ Few complications ✅ Stable pacing parameters The system offers: ⚡ Intracardiac anti-tachycardia pacing 💓 Rate-responsive bradycardia pacing 🛑 Sudden cardiac death preventions 🔜 Boston Scientific aims for FDA approval in 2025. #CardiacRhythmManagement #CRM #LeadlessPacemaker #SICD CM Medical Recruitment

💞 Field Medical starts FIH study for FieldForce Ablation System The FieldForce Ablation System is said to be the first and only contact force pulsed field ablation (PFA) system for the time-efficient treatment of people with ventricular arrhythmias. The Ventricular Catheter Ablation Study (VCAS) will assess the FieldForce system at Na Homolce Hospital in Prague, Czech Republic. VCAS will recruit up to 60 patients at up to five sites worldwide. The system’s potential will be assessed to address the limitations of existing PFA and radiofrequency (RF) ablation systems. It will be conducted in two parts where the VCAS-1 group concentrates on patients afflicted with ventricular tachycardia (VT). On the other hand, the VCAS-2 group is aimed at those encountering frequent premature ventricular complexes (PVCs). The trial seeks to establish that PFA can safely manage and enhance overall outcomes for patients with complex ventricular arrhythmias. Field Medical CEO Steven Mickelsen said: “Our vision at Field Medical is to transform VT ablation into a widely available, one-hour outpatient procedure with improved safety outcomes. “With the promising early data for our VCAS study, in much the same way that PFA transformed AF, the FieldForce Ablation System is optimised to transform how ventricular arrhythmias are treated, offering hope to millions of patients worldwide. “With the strong investor support, renown physician engagement and the groundbreaking potential of our technology, we are set to redefine the standards of cardiac ablation once again.” Read more online: https://lnkd.in/gKCk7rgK 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing

It's Q & A Thursday! Question: When are catheterization codes reported separately with code range 37220-37235 for lower extremity revascularization? Answer: Catherization codes are bundled when related to the intervention reported by codes 37220-37235, however, there are several instances for which catheterizations codes will be reported for the same session/same DOS--- 1️⃣ Diagnostic angiography performed at the same time as the intervention requires a higher degree of selectivity than the one used for the lower extremity intervention. Example: Contralateral extremity angiography in conjunction with a revascularization procedure -- Access at the right common femoral, revascularization of right internal iliac, catheterization and imaging of left leg. Note that the catheterization code is assigned when no intervention is performed on the contralateral side. If an intervention was performed on the left common iliac and then the catheter is moved to the popliteal for additional imaging, that catheter work would not be reported separately. 2️⃣ Diagnostic angiography for the revascularization is performed at the same time as revascularization from a separate access. Example: Catheterization of the aorta for an aortogram may be performed via a left groin puncture, yet the revascularization is performed on the right iliac via a right groin puncture. Note that is both punctures are utilized to facilitate the therapeutic intervention, catheterization will not be assigned for the diagnostic imaging. 3️⃣ Another catheterization is performed through the same access for another diagnostic or therapeutic procedure requiring catheterization in a different vascular bed. Example: Performing a renal PTA in conjunction with a revascularization 4️⃣ A separate vessel punctured for an additional access that is not part of the revascularization procedure and another vessel is selectively catheterized for another purpose. 5️⃣ Another procedure is performed on the same date of service at a different session. #qandathursday #radrx #crackingtheIRcode #circc #interventionalradiologycoding #ivrcoding #ircoding